BLX 1002

Drug Profile

BLX 1002

Alternative Names: BLX-1002

Latest Information Update: 24 Nov 2010

Price : $50

At a glance

  • Originator BEXEL Pharmaceuticals
  • Class Amino acids; Anti-inflammatories; Small molecules
  • Mechanism of Action Interleukin 6 inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Unspecified
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 24 Nov 2010 No development reported - Phase-II for Type-2 diabetes mellitus in Europe (PO)
  • 11 Sep 2008 Pharmacodynamics data from a preclinical trial Diabetes mellitus presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD-2008)
  • 29 Mar 2007 Phase II development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top